Inpeco and Bio-Rad Partner to Connect Total Lab Automation Solution and Smart HPLC Technology
NOVAZZANO, CH and HERCULES, Calif. — October 10, 2018 — Inpeco S.A., the privately held leader in total laboratory automation (TLA) solutions and
Inpeco designs, develops, and manufactures customized TLA solutions that are modular, open, scalable, and fast. Their solutions offer labs automation and traceability, from collection to results improving their diagnostic workflow.
"A distinctive feature of our FlexLab TLA solution is its open connectivity," said Gigi Minola, Inpeco Vice President. "An open system connection gives customers the freedom to choose the instruments they prefer to use for their complete lab automation. We are thrilled to meet our customers' needs by connecting Bio-Rad's D-100 instrument to our TLA solution."
"We are pleased to partner with Inpeco to connect the D-100 System to the Inpeco FlexLab automated track system," said John Hertia,
About Inpeco, S.A.
Since 1990, Inpeco S.A. has specialized in providing automation solutions to improve and simplify the process and operations of any-size laboratories, from collection to result. With 1700 solutions installed all over the world, Inpeco has gained unparalleled expertise in automation, robotics, sample and data management, and patient-related activities. Inpeco was awarded the Frost & Sullivan's 2018 Company of the Year recognition in the Clinical Lab Automation area For more information, visit www.inpeco.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "can," "plan," "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
Lucilla Mariani, Communications Director